Open an account

Alector

ALEC · NASDAQ

$1.97+$0.02 (+1.03%)TodayMarket closed ·
Prev close $1.95

About ALEC

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 103 full-time employees. The company went IPO on 2019-02-07. The firm is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. The company also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.

Employees
103
Headquarters
South San Francisco, California
Listed
Feb 7, 2019
Sector
Health Care
Industry
Biotechnology
Website
alector.com

ALEC key statistics

Market cap
219.96M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.97M
Volume
2.02M
Open price
$1.96
High today
$2.04
Low today
$1.92
52 Week high
$3.34
52 Week low
$1.09

Alector (ALEC) at a glance

Alector (ALEC) last traded at $1.97, with a market cap of 219.96M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.92 and $2.04. The current price is 2.9% above the day's low and 3.4% below its high.

Volume so far is 2.02M shares, below the average of 6.97M shares a day.

Over the past year Alector has ranged from $1.09 to $3.34, and now sits 39% of the way up that range.

Alector met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q2 FY26 it reported -$0.21 per share against an estimate of -$0.2326.

The average analyst price target is $3.16, 60.5% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

57%of 7 analyst ratings say Buy
  • Buy57.1%
  • Hold28.6%
  • Sell14.3%
Price target · 7 analystsAvg $3.16
Low
$1.01
Now
$1.97
High
$6.30

ALEC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 31.5% on average.

  1. Q3 FY24: reported -$0.43 per share against an estimate of -$0.5443
  2. Q4 FY24: reported -$0.02 per share against an estimate of -$0.6494
  3. Q1 FY25: reported -$0.41 per share against an estimate of -$0.4947
  4. Q2 FY25: reported -$0.30 per share against an estimate of -$0.4692
  5. Q3 FY25: reported -$0.34 per share against an estimate of -$0.4157
  6. Q4 FY25: reported -$0.34 per share against an estimate of -$0.3914
  7. Q1 FY26: reported -$0.21 per share against an estimate of -$0.3497
  8. Q2 FY26: reported -$0.21 per share against an estimate of -$0.2326

ALEC news

  • Press releaseGlobe Newswire

    Biotech Brainiacs and Breakthroughs

  • Vandana Singh

    GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releasePRNewswire

    INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint

  • Press releaseGlobe Newswire

    ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

  • Press releaseGlobe Newswire

    ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

  • Press releaseBusiness Wire

    ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Similar companies

Companies in the same industry as Alector

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.